CNTX
Context Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Context Therapeutics dosed the first patient in the Phase 1 CT-202 trialSep 9, 2026
- Context Therapeutics reported positive interim efficacy and safety results from its ongoing Phase 1 trial of CTIM-76Jun 15, 2026
- Context Therapeutics amended its licensing agreement with BioAtla for CT-202May 18, 2026
- Context Therapeutics received FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancerApr 2, 2026
- Context Therapeutics presents ongoing CTIM-76 trial poster at 2025 ASCO meetingJun 2, 2025